Perspective Therapeutics, Inc. Share Price
Equities
CATX
US46489V1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 USD | -6.98% | -13.04% | +198.51% |
Sales 2024 * | 523K 41.15M | Sales 2025 * | 321K 25.29M | Capitalization | 809M 63.66B |
---|---|---|---|---|---|
Net income 2024 * | -54M -4.25B | Net income 2025 * | -64M -5.04B | EV / Sales 2024 * | 1,547 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,517 x |
P/E ratio 2024 * |
-12.2
x | P/E ratio 2025 * |
-11.1
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.45% |
Latest transcript on Perspective Therapeutics, Inc.
1 day | -6.25% | ||
1 week | -13.04% | ||
Current month | -13.04% | ||
1 month | -33.33% | ||
3 months | +0.84% | ||
6 months | +380.00% | ||
Current year | +198.51% |
Managers | Title | Age | Since |
---|---|---|---|
Johan Spoor
CEO | Chief Executive Officer | 52 | 02/02/23 |
Mark Austin
DFI | Director of Finance/CFO | 37 | 30/06/17 |
Jonathan Hunt
DFI | Director of Finance/CFO | 57 | 02/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Heidi Henson
BRD | Director/Board Member | 58 | 31/05/23 |
Lori Woods
CHM | Chairman | 61 | 02/02/23 |
Director/Board Member | 58 | 02/02/23 |
Date | Price | Change | Volume |
---|---|---|---|
07/06/24 | 1.2 | -6.98% | 3,886,883 |
06/06/24 | 1.29 | -8.51% | 6,534,527 |
05/06/24 | 1.41 | +2.17% | 4,157,272 |
04/06/24 | 1.38 | +0.73% | 8,078,992 |
03/06/24 | 1.37 | -0.72% | 7,108,934 |
Delayed Quote Nyse, June 07, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+198.51% | 809M | |
+51.85% | 57.87B | |
+41.08% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- CATX Stock